Första AP-fonden’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.45M | Sell |
19,500
-200
| -1% | -$25.1K | 0.02% | 503 |
|
|
2025
Q1 | $2.18M | Sell |
19,700
-500
| -2% | -$55.3K | 0.02% | 524 |
|
|
2024
Q4 | $2.76M | Sell |
20,200
-2,000
| -9% | -$273K | 0.02% | 518 |
|
|
2024
Q3 | $2.56M | Sell |
22,200
-10,400
| -32% | -$1.2M | 0.02% | 519 |
|
|
2024
Q2 | $4.49M | Sell |
32,600
-1,600
| -5% | -$220K | 0.04% | 380 |
|
|
2024
Q1 | $4.72M | Buy |
34,200
+16,600
| +94% | +$2.29M | 0.04% | 396 |
|
|
2023
Q4 | $2.32M | Sell |
17,600
-600
| -3% | -$79.1K | 0.02% | 518 |
|
|
2023
Q3 | $2.05M | Buy |
+18,200
| New | +$2.05M | 0.02% | 524 |
|
|
2022
Q4 | – | Sell |
-13,600
| Closed | -$1.44M | – | 559 |
|
|
2022
Q3 | $1.44M | Buy |
13,600
+11,000
| +423% | +$1.17M | 0.02% | 522 |
|
|
2022
Q2 | $253K | Buy |
+2,600
| New | +$253K | ﹤0.01% | 561 |
|
|
2020
Q4 | – | Sell |
-14,900
| Closed | -$1.43M | – | 538 |
|
|
2020
Q3 | $1.43M | Buy |
14,900
+2,700
| +22% | +$260K | 0.03% | 473 |
|
|
2020
Q2 | $1.49M | Sell |
12,200
-1,600
| -12% | -$195K | 0.04% | 447 |
|
|
2020
Q1 | $1.19M | Buy |
+13,800
| New | +$1.19M | 0.04% | 412 |
|